Meta-analysis finds no consistent decline in radiation-induced optic neuropathy over three decades

A meta-analysis of 103 studies found no consistent decline in radiation-induced optic neuropathy despite advances in radiotherapy techniques.

KEY POINTS

  • This systematic review and random-effects meta-analysis included 103 studies published between 1994 and 2025, evaluating radiation-induced optic neuropathy (RION) after treatment of intraocular and extraocular tumors. The analysis comprised 36 intraocular tumor studies, predominantly plaque brachytherapy (33 studies) with three proton therapy series, and 67 extraocular tumor studies, including 39 using conventional fractionation and 28 using hypofractionated RT. The investigators evaluated pooled incidence, tumor location, fractionation, radiation dose, diagnostic criteria, and temporal trends.
  • Intraocular tumors showed the highest reported RION incidence, with a pooled estimate of 19.2% (95% CI 13.5–26.6%) across all 36 studies. Excluding two outlying series involving juxtapapillary choroidal melanoma reduced the estimate to approximately 17.0%, but heterogeneity remained substantial (I²=92%). Individual study rates ranged from 0% to 81.7%, reflecting major differences in tumor proximity to the optic disc, radiation technique, dose, and diagnostic criteria.
  • In extraocular tumors, pooled RION incidence was 4.2% (95% CI 2.9–6.0%) after conventionally fractionated RT and 2.6% (95% CI 1.6–4.2%) after hypofractionated RT, using all eligible studies. However, all 28 hypofractionated studies involved CNS tumors, whereas conventionally fractionated cohorts included both CNS and head and neck cancers. Median follow-up was also shorter with hypofractionation (3.4 versus 5.1 years; p<0.001), preventing interpretation of the crude difference as evidence of superior optic safety.
  • Tumor location significantly influenced RION incidence. Across extraocular cohorts, pooled estimates were approximately 2.9% for CNS tumors and 5.8% for head and neck cancers, with meta-regression confirming higher risk in the latter (estimate 0.7185; p=0.0076). Among CNS studies alone, neither fractionation type (p=0.54), dose per fraction (p=0.77), nor EQD2 (p=0.36) was significantly associated with RION incidence, suggesting that differences between treatment populations and optic exposure may be more important than fractionation category alone.
  • Radiation dose to the optic apparatus remained the most consistently reported risk factor, particularly maximum dose to the optic nerves or chiasm. Across individual studies, risk was associated with optic doses exceeding approximately 50–55 Gy, tumor proximity to the visual pathways, larger tumor dimensions, and pre-existing optic pathway impairment. Additional reported factors included diabetes, hypertension, elevated intraocular pressure, retinal detachment, and previous surgery, although these associations were not uniformly evaluated or independently validated across the pooled cohorts.
  • No robust reduction in RION incidence was demonstrated over time, despite major advances in treatment conformality. Publication-year meta-regression showed no statistically significant trend in intraocular tumors (OR per decade 0.87, 95% CI 0.56–1.35; p=0.51), conventionally fractionated extraocular tumors (OR 0.94, 95% CI 0.67–1.34; p=0.74), or CNS tumors (OR 0.90, 95% CI 0.68–1.19; p=0.46). Exploratory analyses suggested possible declines in selected subgroups, but these findings were not robust to outlier exclusion or additional adjustments.
  • Diagnostic heterogeneity substantially affected reported RION rates. Studies used variable definitions based on visual acuity, visual fields, optic disc abnormalities, electrophysiology, MRI, or optical coherence tomography, while some provided no explicit diagnostic criteria. Imaging-based ascertainment was associated with approximately threefold higher reported incidence (OR 3.16, 95% CI 1.45–6.92; p=0.005) in an exploratory model. Wide prediction intervals, incomplete patient-level optic dosimetry, variable follow-up, and inconsistent handling of competing events limit the generalizability of pooled estimates and highlight the need for standardized prospective ophthalmological surveillance.

CLINICAL TAKEAWAY

Radiation-induced optic neuropathy remains an important late complication for patients with intraocular, skull-base, and head and neck tumors involving or approaching the visual pathways, and a consistent decline in its incidence has not been demonstrated despite advances in radiotherapy technology. These findings reinforce the importance of optic-structure dose constraints, individualized assessment of tumor–optic geometry and pre-existing visual impairment, and long-term ophthalmological follow-up, while substantial heterogeneity prevents the pooled rates from being used as universal patient-specific risk estimates.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction